Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
23.87
+0.15 (0.63%)
Nov 21, 2024, 11:27 AM EST - Market open
Xencor Revenue
Xencor had revenue of $10.71M in the quarter ending September 30, 2024, a decrease of -81.90%. This brings the company's revenue in the last twelve months to $85.16M, down -41.37% year-over-year. In the year 2023, Xencor had annual revenue of $168.34M with 2.28% growth.
Revenue (ttm)
$85.16M
Revenue Growth
-41.37%
P/S Ratio
17.25
Revenue / Employee
$304,157
Employees
280
Market Cap
1.67B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 168.34M | 3.76M | 2.28% |
Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
Dec 31, 2019 | 156.70M | 116.10M | 285.93% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fortrea Holdings | 2.98B |
Clover Health Investments | 2.12B |
GoodRx Holdings | 790.39M |
10x Genomics | 629.74M |
Immunocore Holdings | 296.31M |
Galapagos NV | 290.09M |
Dynavax Technologies | 260.81M |
Recursion Pharmaceuticals | 65.18M |
XNCR News
- 14 days ago - Xencor Reports Third Quarter 2024 Financial Results - Business Wire
- 17 days ago - Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease - Business Wire
- 6 weeks ago - Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases - Business Wire
- 6 weeks ago - Xencor Announces Upcoming Change to Board of Directors - Business Wire
- 2 months ago - Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Business Wire
- 2 months ago - Xencor: Vudalimab Development Along With Hidden Gem Candidate - Seeking Alpha
- 2 months ago - Xencor Announces Pricing of $175 Million Public Offering of Common Stock - Business Wire
- 2 months ago - Xencor Announces Proposed Public Offering of Common Stock - Business Wire